Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | PARL | Q9H300 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL300884 | 0.86 | CA12 (0.42) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20522541 | 0.84 | MGLL (0.32) | SMN1; SMN2KMT2ALMNAMGLL | |
| SCHEMBL334846 | 0.82 | MAPK1 (0.40) | ALDH1A1HPGDSMN1; SMN2KMT2ALMNA | |
| SCHEMBL14640220 | 0.81 | ALDH1A1 (0.54) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3565689 | 0.81 | MAPT (0.42) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8433813 | 0.81 | KMT2A (0.50) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13455758 | 0.81 | SMN1; SMN2 (0.44) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5648489 | 0.80 | CA12 (0.47) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27717830 | 0.80 | CA1 (0.55) | ALDH1A1HPGDSMN1; SMN2KMT2ACA12 | |
| SCHEMBL7740161 | 0.79 | CA1 (0.55) | ALDH1A1HPGDKMT2AMEN1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125961-A1 | THERAPEUTIC AGENTS AND USES THEREOF | JANSSEN BIOTECH INC (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3929202-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3149015-B1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210070796-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2021-03-11 | — | — | US | disclosed |
| CN-112028951-A | Micro saponin analogue, synthesis and use thereof | 索隆-基特林癌症研究协会 | 2020-12-04 | — | — | CN | disclosed |
| EP-2935335-B1 | NEW POLYPEPTIDES | AFFIBODY AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| CN-106573951-B | Micro saponin analogue, synthesis and use thereof | 索隆-基特林癌症研究协会 | 2020-09-11 | — | — | CN | disclosed |
| US-20200138986-A1 | THERAPEUTIC AGENTS AND USES THEREOF | JANSSEN BIOTECH, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10626137-B2 | Minimal saponin analogues, synthesis and use thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-04-21 | — | — | US | disclosed |
| US-9957330-B2 | Polypeptides | AFFIBODY AB (SE) | 2018-05-01 | — | — | US | disclosed |
| US-7993650-B2 | Polypeptides having binding affinity for HER2 | AFFIBODY AB (SE) | 2011-08-09 | — | — | US | disclosed |
| CN-1816563-B | Polypeptides having binding affinity for HER2 | AFFIBODY AB | 2011-02-09 | — | — | CN | disclosed |
| US-20100048868-A1 | Polypeptides Having Binding Affinity for Her2 | AFFIBODY AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20090016957-A1 | Polypeptides | AFFIBODY AB (SE) | 2009-01-15 | — | — | US | disclosed |
| EP-1641818-B1 | POLYPEPTIDES HAVING BINDING AFFINITY FOR HER2 | AFFIBODY AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1973934-A1 | POLYPEPTIDES | Affibody AB (SE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007065635-A1 | POLYPEPTIDES | AFFIBODY AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| CN-1816563-A | Polypeptides having binding affinity for HER2 | AFFIBODY AB (SE) | 2006-08-09 | — | — | CN | disclosed |
| EP-1641818-A1 | POLYPEPTIDES HAVING BINDING AFFINITY FOR HER2 | Affibody AB (SE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005003156-A1 | POLYPEPTIDES HAVING BINDING AFFINITY FOR HER2 | AFFIBODY AB (SE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070796-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | DDOST, SI, STT3A | ALDH1A1 4861/4885HPGD 685/4885SMN1; SMN2 3144/4885 |
| US-10626137-B2 | Minimal saponin analogues, synthesis and use thereof | DDOST, SI, STT3A | ALDH1A1 4861/4885HPGD 685/4885SMN1; SMN2 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.